Serotonergic modulation of receptor occupancy in rats treated with l-DOPA after unilateral 6-OHDA lesioning

Journal of Neurochemistry

Volumn 120, Issue 5, 2012, Pages 806-817

  Nahimi, Adjmal ^a   Høltzermann, Mette ^a   Landau, Anne M ^a   Simonsen, Mette ^a   Jakobsen, Steen ^a   Alstrup, Aage Kristian Olsen ^a   Vang, Kim ^a   Møller, Arne ^a   Wegener, Gregers ^a   Gjedde, Albert ^b   Doudet, Doris J ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

5 HT 1A receptor agonist; 6 hydroxydopamine; l DOPA induced dyskinesia; micro positron emission tomography and microdialysis; Parkinson's disease

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; DOPAMINE; DOPAMINE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DISEASE SEVERITY; DOPAMINE RELEASE; DYSKINESIA; FEMALE; IN VIVO STUDY; MICRODIALYSIS; MOTOR ACTIVITY; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; RECEPTOR OCCUPANCY; SEROTONINERGIC NERVE CELL;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANALYSIS OF VARIANCE; ANIMALS; ANTIPARKINSON AGENTS; AUTORADIOGRAPHY; CARBON ISOTOPES; COCAINE; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE UPTAKE INHIBITORS; DYSKINESIA, DRUG-INDUCED; FEMALE; FUNCTIONAL LATERALITY; LEVODOPA; MICRODIALYSIS; MOTOR ACTIVITY; OXIDOPAMINE; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RACLOPRIDE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN; SEROTONERGIC NEURONS; SEROTONIN RECEPTOR AGONISTS;

ANIMALIA; RATTUS;

EID: 84857195565     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2011.07598.x     Document Type: Article

References (52)

1. Abercrombie E., and, Bonatz A., (1990) Effects of l-DOPA on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. Brain Res. 508, 181-187.
2. Ahlskog J. E., and, Muenter M. D., (2001) Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Movement Disord. 16, 448-458.
3. Barnes N. M., and, Sharp T., (1999) A review of central 5-HT receptors and their function. Neuropharmacology 38, 1083-1152.
4. Berthet A., and, Bezard E., (2009) Dopamine receptors and L-dopa-induced dyskinesia. Parkinsonism Related Disord. 15 (Suppl. 4), S8-S12.
5. Breier A., Su T. P., Saunders R., et al. (1997) Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc. Natl Acad. Sci. USA 94, 2569-2574.
6. Carta M., Carlsson T., Kirik D., and, Björklund A., (2007) Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 130 (Pt 7), 1819-1833.
7. Cenci M. A., and, Konradi C., (2010) Maladaptive striatal plasticity in l-DOPA-induced dyskinesia. Progress Brain Res. 183, 209-233.
8. Cenci M. A., and, Lundblad M., (2006) Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia. J. Neurochem. 99, 381-392.
9. Cenci M. A., Lee C. S., and, Björklund A., (1998) L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 10, 2694-2706.
10. Cragg S. J., and, Rice M. E., (2004) DAncing past the DAT at a DA synapse. Trends Neurosci. 27, 270-277.
11. Cumming P., Kuwabara H., Ase A., and, Gjedde A., (1995) Regulation of DOPA decarboxylase activity in brain of living rat. J. Neurochem. 65, 1381-1390.
12. Cumming P., Wong D. F., Dannals R. F., Gillings N., Hilton J., Scheffel U., and, Gjedde A., (2002) The competition between endogenous dopamine and radioligands for specific binding to dopamine receptors. Ann. N Y Acad. Sci. 965, 440-450.
13. Doudet D. J., and, Holden J. E., (2003) Raclopride studies of dopamine release: dependence on presynaptic integrity. Biol. Psychiatry 54, 1193-1199.
14. Doudet D. J., Jivan S., Ruth T. J., and, Holden J. E., (2002) Density and affinity of the dopamine D2 receptors in aged symptomatic and asymptomatic MPTP-treated monkeys: PET studies with [11C]raclopride. Synapse 44, 198-202.
15. Eskow K. L., Dupre K. B., Barnum C. J., Dickinson S. O., Park J. Y., and, Bishop C., (2009) The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats. Synapse 63, 610-620.
16. Esposito E., and, Di Matteo V., (2008) Serotonin-dopamine interaction: an overview. Prog. Brain Res. 172, 3-6.
17. Everett G. M., and, Borcherding J. W., (1970) L-DOPA: effect on concentrations of dopamine, norepinephrine, and serotonin in brains of mice. Science 168, 847-850.
18. Fox S., and, Chuang R., (2008) Parkinson's disease-opportunities for novel therapeutics to reduce the problems of levodopa therapy. Prog. Brain Res. 172, 479-494.
19. de la Fuente-Fernández R., Sossi V., Huang Z., Furtado S., Lu J.-Q., Calne D. B., Ruth T. J., and, Stoessl A. J., (2004) Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain 127 (Pt 12), 2747-2754.
20. Ginovart N., (2005) Imaging the dopamine system with in vivo [11C]raclopride displacement studies: understanding the true mechanism. Mol. Imaging Biol. 7, 45-52.
21. Gjedde A., and, Wong D. F., (1987) Positron tomographic quantitation of neuroreceptors in human brain in vivo - with special reference to the D2 dopamine receptors in caudate nucleus. Neurosurg. Rev. 10, 9-18.
22. Gjedde A., Léger G. C., Cumming P., Yasuhara Y., Evans A. C., Guttman M., and, Kuwabara H., (1993) Striatal L-dopa decarboxylase activity in Parkinson's disease in vivo: implications for the regulation of dopamine synthesis. J. Neurochem. 61, 1538-1541.
23. Gjedde A., Wong D. F., Rosa-Neto P., and, Cumming P., (2005) Mapping neuroreceptors at work: on the definition and interpretation of binding potentials after 20 years of progress. Int. Rev. Neurobiol. 63, 1-20.
24. Innis R. B., Cunningham V. J., Delforge J., Fujita M., Gjedde A., Gunn R. N., Holden J., et al. (2007) Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J. Cereb. Blood Flow Metabol. 27, 1533-1539.
25. Jankovic J., (2005) Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Movement Disord. 20 (Suppl. 11), S11-S16.
26. Kannari K., Yamato H., Shen H., Tomiyama M., Suda T., and, Matsunaga M., (2001) Activation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered L-DOPA in the striatum with nigrostriatal denervation. J. Neurochem. 76, 1346-1353.
27. Kim S. E., Shin I., Oh S. J., Kim S. H., Choe Y. S., Choi Y., and, Kim B. T., (1998) Nicotine-induced dopamine release evaluated with in vivo 3H raclopride binding studies: comparison with in vivo dialysis data. J. Nucl. Med. 39, 54.
28. Laruelle M., (2000) Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J. Cereb. Blood Flow Metabol. 20, 423-451.
29. Lee C. S., Cenci M. A., Schulzer M., and, Björklund A., (2000) Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease. Brain 123 (Pt 7), 1365-1379.
30. Lindgren H., and, Andersson D., (2010) l-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia. J. Neurochem. 112, 1465-1476.
31. Logan J., Fowler J. S., Volkow N. D., Wang G. J., Ding Y. S., and, Alexoff D. L., (1996) Distribution volume ratios without blood sampling from graphical analysis of PET data. J. Cereb. Blood Flow Metabol. 16, 834-840.
32. Mawlawi O., Martinez D., Slifstein M., Broft A., Chatterjee R., Hwang D.-R., Huang Y., et al. (2001) Imaging human mesolimbic dopamine transmission with positron emission tomography: I. accuracy and precision of D2 receptor parameter measurements in ventral striatum. J. Cereb. Blood Flow Metabol. 21, 1034-1057.
33. Mignon L. J., and, Wolf W. A., (2005) 8-hydroxy-2-(di-n-propylamino) tetralin reduces striatal glutamate in an animal model of Parkinson's disease. Neuroreport 16, 699-703.
34. Miller D. W., and, Abercrombie E. D., (1999) Role of high-affinity dopamine uptake and impulse activity in the appearance of extracellular dopamine in striatum after administration of exogenous L-DOPA. Studies in intact and 6-hydroxydopamine-treated rats. J. Neurochem. 72, 1516-1522.
35. Møller M., Jakobsen S., and, Gjedde A., (2007) Parametric and regional maps of free serotonin 5HT1A receptor sites in human brain as function of age in healthy humans. Neuropsychopharmacology 32, 1707-1714.
36. Navailles S., Bioulac B., Gross C., and, De Deurwaerdère P., (2011) Chronic L-DOPA therapy alters central serotonergic function and L-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson's disease. Neurobiol. Dis. 41, 585-590.
37. Ng K. Y., Chase T. N., Colburn R. W., and, Kopin I. J., (1970) L-Dopa-induced release of cerebral monoamines. Science 170, 76-77.
38. Pavese N., Evans A. H., Tai Y. F., Hotton G., Brooks D. J., Lees A. J., and, Piccini P., (2006) Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study. Neurology 67, 1612-1617.
39. Pedersen K., Simonsen M., Østergaard D. S., Munk L. O., Rosa-Neto P., Olsen K. A., Jensen B. S., Møller A., and, Cumming P., (2007) Mapping the amphetamine-evoked changes in [11C]raclopride binding in living rat using small animal PET: modulation by MAO-inhibition. Neuroimage 35, 38-46.
40. Reith J., Cumming P., and, Gjedde A., (1998) Enhanced [3H]DOPA and [3H]dopamine turnover in striatum and frontal cortex in vivo linked to glutamate receptor antagonism. J. Neurochem. 70, 1979-1985.
41. Rinne J. O., Laihinen A., Rinne U. K., NÃgren K., Bergman J., and, Ruotsalainen U., (1993) PET study on striatal dopamine D2 receptor changes during the progression of early Parkinson's disease. Movement Disord. 8, 134-138.
42. Rinne J. O., Laihinen A., Ruottinen H., Ruotsalainen U., NÃgren K., Lehikoinen P., Oikonen V., and, Rinne U.K., (1995) Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride. J. Neurol. Sci. 132, 156-161.
43. Rubins D. J., Melega W. P., Lacan G., Way B., Plenevaux A., Luxen A., and, Cherry S. R., (2003) Development and evaluation of an automated atlas-based image analysis method for microPET studies of the rat brain. NeuroImage 20, 2100-2118.
44. Sossi V., Dinelle K., Topping G. J., Holden J. E., Doudet D., Schulzer M., Ruth T. J., et al. (2009) Dopamine transporter relation to levodopa-derived synaptic dopamine in a rat model of Parkinson's: an in vivo imaging study. J. Neurochem. 109, 85-92.
45. Stamford J. A., Davidson C., McLaughlin D. P., and, Hopwood S. E., (2000) Control of dorsal raphé 5-HT function by multiple 5-HT(1) autoreceptors: parallel purposes or pointless plurality. Trends Neurosci. 23, 459-465.
46. Tanaka H., Kannari K., Maeda T., Tomiyama M., Suda T., and, Matsunaga M., (1999) Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport 10, 631-4.
47. Tedroff J., Pedersen M., Aquilonius M. S., Hartvig P., Jacobsson G., and, LÃngström B., (1996) Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET. Neurology 46, 1430-6.
48. Toga W. A., Santori M. E., Hazani R., and, Ambach K., (1995) A 3D digital map of rat brain. Brain Res. Bull. 38, 77-85.
49. Turjanski N., Lees A. J., and, Brooks D. J., (1997) In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias. Neurology 49, 717-723.
50. Wegener G., Volke V., and, Rosenberg R., (2000) Endogenous nitric oxide decreases hippocampal levels of serotonin and dopamine in vivo. Br. J. Pharmacol. 130, 575-580.
51. Wong D. F., Pearlson G. D., Tune L. E., Young L. T., Meltzer C. C., Dannals R. F., Ravert H. T., et al. (1997) Quantification of neuroreceptors in the living human brain: IV. Effect of aging and elevations of D2-like receptors in schizophrenia and bipolar illness. J. Cereb. Blood Flow Metabol. 17, 331-342.
52. Yamada H., Aimi Y., Nagatsu I., Taki K., Kudo M., and, Arai R., (2007) Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats. Neurosci. Res. 59, 1-7.